| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
19,738 |
18,160 |
$1.34M |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
21,440 |
19,928 |
$1.00M |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
1,748 |
1,682 |
$131K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
1,788 |
1,738 |
$61K |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
3,696 |
3,561 |
$58K |
| S0302 |
Completed early periodic screening diagnosis and treatment (epsdt) service (list in addition to code for appropriate evaluation and management service) |
2,337 |
2,239 |
$55K |
| 36415 |
Collection of venous blood by venipuncture |
14,199 |
12,900 |
$49K |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
1,543 |
1,498 |
$37K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
984 |
943 |
$28K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
308 |
304 |
$24K |
| 90472 |
Immunization administration, each additional vaccine (list separately) |
1,152 |
1,127 |
$23K |
| 99215 |
Prolong outpt/office vis |
166 |
161 |
$23K |
| 99392 |
Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) |
225 |
217 |
$17K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
1,732 |
1,642 |
$17K |
| 99391 |
Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) |
237 |
200 |
$15K |
| 84443 |
Thyroid stimulating hormone (TSH) |
854 |
840 |
$13K |
| 99393 |
Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) |
185 |
180 |
$13K |
| 99394 |
Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) |
176 |
156 |
$12K |
| 80053 |
Comprehensive metabolic panel |
1,236 |
1,162 |
$12K |
| 80061 |
Lipid panel |
1,001 |
977 |
$11K |
| 71046 |
Radiologic examination, chest; 2 views |
609 |
590 |
$11K |
| 83036 |
Hemoglobin; glycosylated (A1C) |
1,262 |
1,240 |
$11K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
1,773 |
1,559 |
$10K |
| 85027 |
|
1,715 |
1,595 |
$9K |
| G0108 |
Diabetes outpatient self-management training services, individual, per 30 minutes |
282 |
244 |
$9K |
| 90686 |
|
1,333 |
1,278 |
$8K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
151 |
149 |
$7K |
| X5622 |
|
564 |
545 |
$7K |
| 99395 |
Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years |
56 |
56 |
$5K |
| 80048 |
Basic metabolic panel (calcium, ionized) |
652 |
613 |
$5K |
| 99421 |
|
252 |
226 |
$5K |
| 99188 |
|
557 |
544 |
$5K |
| 92551 |
|
909 |
892 |
$4K |
| 96127 |
|
1,182 |
1,132 |
$4K |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
33 |
29 |
$4K |
| 82306 |
Vitamin D; 25 hydroxy, includes fraction(s), if performed |
110 |
109 |
$3K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
257 |
231 |
$2K |
| J1050 |
Injection, medroxyprogesterone acetate, 1 mg |
28 |
27 |
$2K |
| 99442 |
|
87 |
52 |
$2K |
| 91320 |
|
31 |
27 |
$2K |
| 81001 |
|
644 |
604 |
$2K |
| 77067 |
Screening mammography, bilateral, including computer-aided detection |
26 |
25 |
$2K |
| 87624 |
Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types |
39 |
39 |
$1K |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
34 |
34 |
$1K |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
148 |
143 |
$1K |
| 87807 |
|
95 |
91 |
$1K |
| 99396 |
Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years |
12 |
12 |
$1K |
| G0145 |
Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with screening by automated system and manual rescreening under physician supervision |
41 |
41 |
$1K |
| 90682 |
|
29 |
29 |
$1K |
| 90715 |
|
152 |
137 |
$1K |
| 87210 |
|
199 |
188 |
$1K |
| 99441 |
|
75 |
46 |
$911.93 |
| 80050 |
General health panel |
15 |
15 |
$817.11 |
| 99173 |
|
916 |
894 |
$766.44 |
| 87389 |
Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies |
30 |
30 |
$760.67 |
| 86803 |
|
47 |
47 |
$718.71 |
| 90480 |
|
28 |
26 |
$675.86 |
| 82728 |
|
46 |
44 |
$607.41 |
| 87081 |
|
171 |
164 |
$602.98 |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
15 |
15 |
$573.45 |
| 81025 |
|
60 |
57 |
$550.97 |
| 0072A |
|
12 |
12 |
$522.96 |
| 99000 |
|
57 |
54 |
$444.00 |
| G2211 |
Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) |
348 |
330 |
$431.42 |
| 0124A |
|
17 |
13 |
$405.69 |
| 90651 |
|
108 |
103 |
$260.65 |
| 87186 |
|
27 |
24 |
$210.49 |
| 90460 |
Immunization administration through 18 years of age via any route, first or only component |
25 |
12 |
$180.00 |
| 96110 |
Developmental screening, with scoring and documentation, per standardized instrument |
12 |
12 |
$141.86 |
| 90473 |
|
13 |
12 |
$134.45 |
| 84439 |
|
13 |
13 |
$127.66 |
| 96161 |
|
65 |
57 |
$98.92 |
| 86308 |
|
14 |
14 |
$89.83 |
| 86140 |
|
14 |
13 |
$55.00 |
| G0008 |
Administration of influenza virus vaccine |
127 |
125 |
$41.72 |
| 81003 |
|
17 |
17 |
$36.75 |
| 90677 |
|
26 |
26 |
$15.00 |
| 90633 |
|
39 |
28 |
$0.00 |
| 90734 |
|
144 |
128 |
$0.00 |
| 90670 |
|
59 |
56 |
$0.00 |
| 90710 |
|
12 |
12 |
$0.00 |
| 90696 |
|
12 |
12 |
$0.00 |
| 90680 |
|
13 |
12 |
$0.00 |